Small Molecules

28 Nov 2017 The European Medicines Agency accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
27 Nov 2017 Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag New Drug Application (NDA) with Priority Review
27 Nov 2017 AIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
27 Nov 2017 OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy
27 Nov 2017 Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson
27 Nov 2017 TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma
27 Nov 2017 Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse(R) in Patients with Lambert-Eaton Myasthenic Syndrome
27 Nov 2017 AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan
27 Nov 2017 Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
24 Nov 2017 Phase III study program with Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority
23 Nov 2017 GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta
22 Nov 2017 Khondrion Presents Phase II KHENERGY Trial Data
22 Nov 2017 DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting
22 Nov 2017 Galapagos initiates Phase 1 study with novel CF corrector GLPG3221
21 Nov 2017 Lead Pharma Achieves Third Milestone in Sanofi Collaboration for Development of Autoimmune Diseases Treatments
21 Nov 2017 Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial of NVK-002 for the Treatment of Myopia in Children
21 Nov 2017 FDA approves first two-drug regimen for certain patients with HIV
21 Nov 2017 Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor
21 Nov 2017 Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis
21 Nov 2017 Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
21 Nov 2017 Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse(R) in Ambulatory Patients with Spinal Muscular Atrophy (SMA)
21 Nov 2017 Cytokinetics Announces Negative Results From VITALITY-ALS
21 Nov 2017 ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma
20 Nov 2017 European Commission Extends License for Janssen’s ZYTIGA® Plus Prednisone / Prednisolone to Include Earlier Stage Prostate Cancer Patients
20 Nov 2017 Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing